Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Credit agrmnt [a]
Appointed director
Monthly oper. report

ACCENTIA BIOPHARMACEUTICALS INC (ABPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/15/2013 8-K Quarterly results
03/07/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/23/2012 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
10/15/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/14/2012 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "For further information, please visit: http://www.biovest.com Forward-Looking Statements: Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements about Biovest and its product candidate, BiovaxID™ and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, Health Canada or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as “may,” “could,” “would,” “should,” “believe..."
06/21/2012 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Subscription Agreement",
"Form of Common Stock Purchase Warrant"
06/07/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Secured Promissory Note, in the original principal amount of $1,500,000 payable by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Common Stock Purchase Warrant, issued by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Security Agreement, by Accentia Biopharmaceuticals, Inc. in favor of Pabeti, Inc",
"Amendment No. 1 to Plan Convertible Promissory Note, between Accentia Biopharmaceuticals, Inc. and Dennis Ryll"
04/13/2012 8-K/A Form 8-K - Current report [amend]
03/08/2012 8-K Submission of Matters to a Vote of Security Holders
11/07/2011 8-K Form 8-K - Current report
11/04/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
09/20/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Joins National Organization for Rare Disorders Corporate Council"
09/14/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Announces that FDA Grants Orphan Drug Status for Revimmune™ Therapy for the Prevention of Graft-Versus-Host Disease in Bone Marrow Transplant TAMPA, FL - September 14, 2011 - Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc. , today jointly announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Revimmune™, the Company's proprietary system-of-care based on high-dose administration of Cytoxan® , for the prevention of graft-versus-host disease following bone marrow transplant. GVHD is a life-threatening autoimmune complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted cells trigger an immune attack on the transplant recipient's body. ..."
06/24/2011 8-K Form 8-K - Current report
06/23/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Announces that FDA grants Orphan Drug Status for Revimmune™ Therapy for the Treatment of Two Autoimmune Diseases: Systemic Sclerosis & Hemolytic Anemia TAMPA, FL - June 23, 2011 - Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Revimmune™, the Company's proprietary system-of-care based on high-dose administration of Cytoxan® , for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia. Based on an exclusive world-wide license from Johns Hopkins University and a strategic agreement with Baxter Corporation, Accentia intends to conduct multiple clinical trials evaluating Revimmune therapy for the treatment of a range of autoimmune dis..."
05/04/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Accentia Biopharmaceuticals Announces that Revimmune™ Autoimmune Disease Therapy is Featured in Peer-review Journal"
03/15/2011 8-K Form 8-K - Current report
01/21/2011 8-K Form 8-K - Current report
01/06/2011 8-K Form 8-K - Current report
12/03/2010 8-K Form 8-K - Current report
11/23/2010 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Amended and Restated Articles of Incorporation of Accentia Biopharmaceuticals, Inc",
"Amended and Restated Bylaws of Accentia Biopharmaceuticals, Inc",
"Notice of Effectiveness",
"Accentia Biopharmaceuticals and its majority-owned subsidiary, Biovest International, Emerge from Chapter 11 Reorganization TAMPA, FLORIDA - November 17, 2010—Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc. have both successfully completed their reorganizations, pursuant to the respective Plans of Reorganization approved by the bankruptcy court. According to Samuel S. Duffey who serves as President & General Counsel for both Accentia and Biovest, “Today marks an exciting new beginning for Accentia and Biovest, as both companies have emerged as much stronger, more financially secure organizations. As such, we are preparing to report significant new milestones that we believe will reflect the enormo..."
11/02/2010 8-K Form 8-K - Current report
10/25/2010 8-K Filed a monthly operating report
Docs: "Biovest Announces $7 Million Financing Required to Exit from Reorganization and Advance Key Regulatory and Commercial Strategies for BiovaxID ® Cancer Vaccine TAMPA, FL and MINNEAPOLIS, MN - October 25, 2010 - Biovest International, Inc. today announced that the Company has entered into definitive loan documents and other agreements for the issuance of $7 million of convertible debtor-in-possession term notes and common stock purchase warrants to institutional investors. ROTH Capital Partners, LLC acted as the exclusive placement agent. The closing occurred on October 19 th , 2010, subject to the Court entering a final order approving the transaction. On October 25, 2010, the Court entered a Final Order approving this financing transaction. Biovest intends to use the proceeds from the DIP ...",
"Monthly Operating Report of Accentia Biopharmaceuticals, Inc. for the period September 1, 2010 through September 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17795-KRM Document No. 1396"
09/24/2010 8-K Form 8-K - Current report
08/20/2010 8-K Form 8-K - Current report
07/26/2010 8-K Form 8-K - Current report
06/25/2010 8-K Filed a monthly operating report
Docs: "Monthly Operating Report of Accentia Biopharmaceuticals, Inc. for the period May 1, 2010 through May 31, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17795-KRM Document No. 730"
06/01/2010 8-K Form 8-K - Current report
05/26/2010 8-K Filed a monthly operating report
Docs: "Monthly Operating Report of Accentia Biopharmaceuticals, Inc. for the period April 1, 2010 through April 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17795-KRM Document No. 680"
04/26/2010 8-K Filed a monthly operating report
Docs: "Monthly Operating Report of Accentia Biopharmaceuticals, Inc. for the period March 1, 2010 through March 31, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17795-KRM Document No. 646"
03/23/2010 8-K Form 8-K - Current report
02/22/2010 8-K Form 8-K - Current report
01/20/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy